Last edition
News about "Guselkumab"
Johnson & Johnson’s IL-23 inhibitor becomes the first in its class to include evidence of structural joint damage inhibition in adults with active psoriatic arthritis.
Guselkumab | 30/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members